The HRA2pl fusion peptide exerts
acute respiratory infections
fusion peptide
human respiratory virus
paramyxovirus
pneumovirus
syncytium size
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
12
2022
accepted:
29
03
2023
medline:
9
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Acute respiratory infections are a group of diseases caused by viruses, bacteria, and parasites that mainly affect children until the age of 5 and immunocompromised senior adults. In Mexico, these infections are the main cause of morbidity in children, with more than 26 million cases of respiratory infections reported by the Secretariat of Health, in 2019. The human respiratory syncytial virus (hRSV), the human metapneumovirus (hMPV), and the human parainfluenza-2 (hPIV-2) are responsible for many respiratory infections. Currently, palivizumab, a monoclonal antibody against the fusion protein F, is the treatment of choice against hRSV infections. This protein is being studied for the design of antiviral peptides that act by inhibiting the fusion of the virus and the host cell. Therefore, we examined the antiviral activity of the HRA2pl peptide, which competes the heptad repeat A domain of the F protein of hMPV. The recombinant peptide was obtained using a viral transient expression system. The effect of the fusion peptide was evaluated with an
Identifiants
pubmed: 37153148
doi: 10.3389/fcimb.2023.1125135
pmc: PMC10157160
doi:
Substances chimiques
HRA2pl peptide
0
Antiviral Agents
0
Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1125135Informations de copyright
Copyright © 2023 Meza, Lara, Gómez, Rodríguez, Hernández and Mendoza.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Antimicrob Agents Chemother. 2008 Jan;52(1):279-87
pubmed: 17967906
J Cell Biol. 2003 Oct 27;163(2):363-74
pubmed: 14581458
Sci Rep. 2019 Jan 30;9(1):929
pubmed: 30700747
Minerva Pediatr. 2018 Dec;70(6):553-565
pubmed: 30334622
Vaccine. 2017 Jan 11;35(3):469-480
pubmed: 27908639
Virol J. 2013 Jul 27;10:245
pubmed: 23890410
Lancet Infect Dis. 2015 Dec;15(12):1398-408
pubmed: 26511956
Clin Dev Immunol. 2013;2013:210490
pubmed: 24363757
Immunol Rev. 2009 Jan;227(1):75-86
pubmed: 19120477
Eur J Biochem. 2000 Sep;267(17):5421-6
pubmed: 10951200
Int J Biol Sci. 2021 Sep 27;17(14):4073-4091
pubmed: 34671221
J Ethnopharmacol. 2013 Jan 9;145(1):146-51
pubmed: 23123794
PLoS One. 2020 Dec 28;15(12):e0244093
pubmed: 33370354
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12891-6
pubmed: 16118271
Ital J Pediatr. 2013 Mar 27;39:22
pubmed: 23536956
BMC Infect Dis. 2009 Jul 05;9:106
pubmed: 19575815
PLoS One. 2017 Mar 16;12(3):e0173504
pubmed: 28301570
Clin Microbiol Rev. 2010 Jan;23(1):74-98
pubmed: 20065326
Viruses. 2015 Mar 06;7(3):996-1019
pubmed: 25757061
J Immunol Res. 2014;2014:515984
pubmed: 25013817
Virus Res. 2015 Nov 2;209:128-35
pubmed: 25738581
PLoS One. 2017 Aug 10;12(8):e0182321
pubmed: 28797053
Eurasian J Med. 2021 Jun;53(2):123-126
pubmed: 34177295
Infect Dis Ther. 2017 Sep;6(3):383-411
pubmed: 28653300
N Engl J Med. 2020 Jul 30;383(5):426-439
pubmed: 32726529
Planta. 2015 Jul;242(1):69-76
pubmed: 25828350
BMC Vet Res. 2019 May 29;15(1):178
pubmed: 31142304
Res Vet Sci. 2009 Dec;87(3):482-7
pubmed: 19435637
Gac Med Mex. 2020;156(4):265-272
pubmed: 32831337
Pediatr Blood Cancer. 2011 Aug;57(2):350-1
pubmed: 21671370
Viruses. 2020 Mar 20;12(3):
pubmed: 32245118
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9288-93
pubmed: 15964978
J Infect Dis. 2019 Oct 22;220(11):1802-1815
pubmed: 31402384